Open Joint-Stock Company Human Stem Cells Institute
Human Stem Cells Institute PJSC (HSCI, MOEX: ISKJ) is a Russian public biotech company founded in 2003.
All edits
Today, HSCI is a strategic investor with diversified assets in high-growth markets related to the development and introduction of innovative drugs, medical devices, genetic testing & genomic analysis, advanced medical and healthcare services.
HSCI invests in various areas and manages assets at different stages of development (startups, early growth companies, mature companies with positive cash flows and stable margins).
As of now, HSCI is the parent holding company which owns over 10 subsidiaries, including one MOEX issuer (IMCB, ticker: GEMA) and five Skolkovo residents.
The HSCI Group aims to improve quality of life and increase life expectancy by pushing forward personalized, predictive and preventive medicine, as well as integrating recent advances in medical genetics, bioinformatics, gene therapy, cell technologies & tissue engineering, biobanking and biopharmaceutics into clinical practice and healthcare.
HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of advanced biomedical technologies, including such segments as:
Gene therapy (gene therapy drugs, gene-activated matrices)
Regenerative medicine (cell-based services, tissue engineering products)
Medical genetics, including reproductive genetics (lab & clinics /genetic testing and counselling)
Bio-insurance
Biopharmaceutics (within the international SуnBio project)
The Company strives to foster a new culture of medical care linked to the concepts of personalized and preventive medicine.
HSCI owns Gemabank– a family cord blood stem cell bank, the largest in Russia and the CIS, as well as Reprobank® — a reproductive cell and tissue bank (personal storage, donation).
The Company has brought to the market Neovasculgen — the first Russian gene therapy drug for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI), caused by atherosclerosis. Neovasculgen is a first-in-class drug whose action mechanism – therapeutic angiogenesis – introduces a new approach to treating ischemia. As of today, the drug has marketing authorization in both Russia and Ukraine.
HSCI has introduced to the Russian aesthetic medicine market SPRS-therapy – a set of personalized diagnostics and treatment procedures based on the innovative cell technology which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
HSCI is implementing a socially significant Genetico project for the development of its own Medical genetics center & lab to provide a range of genetic testing and counseling services with the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases. Among others, Genetico center & molecular diagnostic lab provide such types of genetic tests and analysis as DNA screening, diagnostic panels for specific disease categories and cases, non-invasive prenatal testing (NIPT), PGS/PGD (preimplantation genetic screening / diagnosis of early-stage embryos for chromosomal abnormalities / monogenic inherited diseases during an IVF cycle). The company has also brought to the Russian market the services in such areas as oncogenetics (e.g. identification of genetic predisposition to breast and/or ovarian cancer) and bioinformatics based on NGS (e.g. genome sequencing and interpretation, including Whole Exome Sequencing for the diagnosis of complicated inherited disease cases; extended diagnostic panels for specific disease categories and cases, including oncological diseases). Starting 2013 the Genetico® services are offered based on HSCI’s new laboratory and production complex in Moscow.
The Company intends to develop its products not only for the Russian market but for international markets as well.
HSCI and its subsidiary Cryonix are co-investors in SynBio – a long-term multilateral project to create new unique medicines (first-in-class and BioBetters) for the Russian and international markets with the aim of achieving progress in the treatment of socially significant diseases. The SynBio project unites top Russian and international companies engaged in biotech/biopharm R&D and is supported by an investment from RUSNANO (a state-owned fund for supporting nanotechnologies).
HSCI actively promotes scientific engagement and discussion of fields of research related to its core business areas. This includes holding the Annual International symposium “Current Topics in Gene and Cell Technologies” and publishing the scientific and analytical journal Genes & Cells (former «Cell Transplantology and Tissue Engineering»).
In December 2009 Human Stem Cells Institute conducted its IPO on the MICEX (ticker: ISKJ), becoming the first biotech company in Russia to go public. HSCI is traded on the iIM (Innovation & Investment Market) – a exchange sector created as a platform for innovative and growing companies. Today MICEX is part of the Moscow Exchange (the ME MICEX-RTS).
Open Joint-Stock Company Human Stem Cells Institute
Human Stem Cells Institute PJSC (HSCI, MOEX: ISKJ) is a Russian public biotech company founded in 2003.
Today, HSCI is a strategic investor with diversified assets in high-growth markets related to the development and introduction of innovative drugs, medical devices, genetic testing & genomic analysis, advanced medical and healthcare services.
HSCI invests in various areas and manages assets at different stages of development (startups, early growth companies, mature companies with positive cash flows and stable margins).
As of now, HSCI is the parent holding company which owns over 10 subsidiaries, including one MOEX issuer (IMCB, ticker: GEMA) and five Skolkovo residents.
The HSCI Group aims to improve quality of life and increase life expectancy by pushing forward personalized, predictive and preventive medicine, as well as integrating recent advances in medical genetics, bioinformatics, gene therapy, cell technologies & tissue engineering, biobanking and biopharmaceutics into clinical practice and healthcare.
HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of advanced biomedical technologies, including such segments as:
Gene therapy (gene therapy drugs, gene-activated matrices)
Regenerative medicine (cell-based services, tissue engineering products)
Medical genetics, including reproductive genetics (lab & clinics /genetic testing and counselling)
Bio-insurance
Biopharmaceutics (within the international SуnBio project)
The Company strives to foster a new culture of medical care linked to the concepts of personalized and preventive medicine.
HSCI owns Gemabank– a family cord blood stem cell bank, the largest in Russia and the CIS, as well as Reprobank® — a reproductive cell and tissue bank (personal storage, donation).
The Company has brought to the market Neovasculgen — the first Russian gene therapy drug for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI), caused by atherosclerosis. Neovasculgen is a first-in-class drug whose action mechanism – therapeutic angiogenesis – introduces a new approach to treating ischemia. As of today, the drug has marketing authorization in both Russia and Ukraine.
HSCI has introduced to the Russian aesthetic medicine market SPRS-therapy – a set of personalized diagnostics and treatment procedures based on the innovative cell technology which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
HSCI is implementing a socially significant Genetico project for the development of its own Medical genetics center & lab to provide a range of genetic testing and counseling services with the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases. Among others, Genetico center & molecular diagnostic lab provide such types of genetic tests and analysis as DNA screening, diagnostic panels for specific disease categories and cases, non-invasive prenatal testing (NIPT), PGS/PGD (preimplantation genetic screening / diagnosis of early-stage embryos for chromosomal abnormalities / monogenic inherited diseases during an IVF cycle). The company has also brought to the Russian market the services in such areas as oncogenetics (e.g. identification of genetic predisposition to breast and/or ovarian cancer) and bioinformatics based on NGS (e.g. genome sequencing and interpretation, including Whole Exome Sequencing for the diagnosis of complicated inherited disease cases; extended diagnostic panels for specific disease categories and cases, including oncological diseases). Starting 2013 the Genetico® services are offered based on HSCI’s new laboratory and production complex in Moscow.
The Company intends to develop its products not only for the Russian market but for international markets as well.
HSCI and its subsidiary Cryonix are co-investors in SynBio – a long-term multilateral project to create new unique medicines (first-in-class and BioBetters) for the Russian and international markets with the aim of achieving progress in the treatment of socially significant diseases. The SynBio project unites top Russian and international companies engaged in biotech/biopharm R&D and is supported by an investment from RUSNANO (a state-owned fund for supporting nanotechnologies).
HSCI actively promotes scientific engagement and discussion of fields of research related to its core business areas. This includes holding the Annual International symposium “Current Topics in Gene and Cell Technologies” and publishing the scientific and analytical journal Genes & Cells (former «Cell Transplantology and Tissue Engineering»).
In December 2009 Human Stem Cells Institute conducted its IPO on the MICEX (ticker: ISKJ), becoming the first biotech company in Russia to go public. HSCI is traded on the iIM (Innovation & Investment Market) – a exchange sector created as a platform for innovative and growing companies. Today MICEX is part of the Moscow Exchange (the ME MICEX-RTS).
Find more companies like Open Joint-Stock Company Human Stem Cells Institute
